BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21293199)

  • 1. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.
    Ciaranello AL; Lockman S; Freedberg KA; Hughes M; Chu J; Currier J; Wood R; Holmes CB; Pillay S; Conradie F; McIntyre J; Losina E; Walensky RP;
    AIDS; 2011 Feb; 25(4):479-92. PubMed ID: 21293199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.
    Holmes CB; Zheng H; Martinson NA; Freedberg KA; Walensky RP
    Clin Infect Dis; 2006 Jun; 42(12):1772-80. PubMed ID: 16705586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
    Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
    AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
    Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.
    Lindsey JC; Hughes MD; Violari A; Eshleman SH; Abrams EJ; Bwakura-Dangarembizi M; Barlow-Mosha L; Kamthunzi P; Sambo PM; Cotton MF; Moultrie H; Khadse S; Schimana W; Bobat R; Zimmer B; Petzold E; Mofenson LM; Jean-Philippe P; Palumbo P;
    Pediatr Infect Dis J; 2014 Aug; 33(8):846-54. PubMed ID: 25222305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral therapies in women after single-dose nevirapine exposure.
    Lockman S; Hughes MD; McIntyre J; Zheng Y; Chipato T; Conradie F; Sawe F; Asmelash A; Hosseinipour MC; Mohapi L; Stringer E; Mngqibisa R; Siika A; Atwine D; Hakim J; Shaffer D; Kanyama C; Wools-Kaloustian K; Salata RA; Hogg E; Alston-Smith B; Walawander A; Purcelle-Smith E; Eshleman S; Rooney J; Rahim S; Mellors JW; Schooley RT; Currier JS;
    N Engl J Med; 2010 Oct; 363(16):1499-509. PubMed ID: 20942666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
    Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM
    BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS; Chang EY; Bentley TG; Juday T; Uy J
    J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
    Coovadia A; Abrams EJ; Strehlau R; Shiau S; Pinillos F; Martens L; Patel F; Hunt G; Tsai WY; Kuhn L
    JAMA; 2015 Nov; 314(17):1808-17. PubMed ID: 26529159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral treatment for children with peripartum nevirapine exposure.
    Palumbo P; Lindsey JC; Hughes MD; Cotton MF; Bobat R; Meyers T; Bwakura-Dangarembizi M; Chi BH; Musoke P; Kamthunzi P; Schimana W; Purdue L; Eshleman SH; Abrams EJ; Millar L; Petzold E; Mofenson LM; Jean-Philippe P; Violari A
    N Engl J Med; 2010 Oct; 363(16):1510-20. PubMed ID: 20942667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
    Lockman S; Hughes M; Sawe F; Zheng Y; McIntyre J; Chipato T; Asmelash A; Rassool M; Kimaiyo S; Shaffer D; Hosseinipour M; Mohapi L; Ssali F; Chibowa M; Amod F; Halvas E; Hogg E; Alston-Smith B; Smith L; Schooley R; Mellors J; Currier J;
    PLoS Med; 2012; 9(6):e1001236. PubMed ID: 22719231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    Coovadia A; Abrams EJ; Stehlau R; Meyers T; Martens L; Sherman G; Hunt G; Hu CC; Tsai WY; Morris L; Kuhn L
    JAMA; 2010 Sep; 304(10):1082-90. PubMed ID: 20823434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
    Simpson KN; Jones WJ; Rajagopalan R; Dietz B
    Clin Drug Investig; 2007; 27(12):807-17. PubMed ID: 18020538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
    ; de Vincenzi I
    Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
    Simpson KN; Pei PP; Möller J; Baran RW; Dietz B; Woodward W; Migliaccio-Walle K; Caro JJ
    Pharmacoeconomics; 2013 May; 31(5):427-44. PubMed ID: 23620210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
    Marseille E; Kahn JG; Mmiro F; Guay L; Musoke P; Fowler MG; Jackson JB
    Lancet; 1999 Sep; 354(9181):803-9. PubMed ID: 10485721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
    Simpson KN; Jones WJ; Rajagopalan R; Dietz B
    Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.